Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harte Hanks (HHS) Gains from Sales and Divestitures (2019 - 2022)

Harte Hanks (HHS) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $69110.0 as the latest value for Q4 2022.

  • On a quarterly basis, Gains from Sales and Divestitures rose 1566.91% to $69110.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $69110.0, a 1566.91% increase, with the full-year FY2022 number at $69110.0, up 1566.91% from a year prior.
  • Gains from Sales and Divestitures was $69110.0 for Q4 2022 at Harte Hanks, up from $4146.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $69110.0 in Q4 2022 to a low of $4146.0 in Q4 2021.
  • A 3-year average of $27096.0 and a median of $8032.0 in 2020 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 48.38% in 2021, then soared 1566.91% in 2022.
  • Harte Hanks' Gains from Sales and Divestitures stood at $8032.0 in 2020, then plummeted by 48.38% to $4146.0 in 2021, then skyrocketed by 1566.91% to $69110.0 in 2022.
  • Per Business Quant, the three most recent readings for HHS's Gains from Sales and Divestitures are $69110.0 (Q4 2022), $4146.0 (Q4 2021), and $8032.0 (Q4 2020).